# Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts

> **NCT02246738** · — · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 87 (actual)

## Conditions studied

- Urothelial Carcinoma of the Bladder

## Interventions

- **OTHER:** Blood Collection

## Key facts

- **NCT ID:** NCT02246738
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2018-08
- **Final completion:** 2020-10
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02246738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02246738, "Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02246738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*